SE0200843D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0200843D0
SE0200843D0 SE0200843A SE0200843A SE0200843D0 SE 0200843 D0 SE0200843 D0 SE 0200843D0 SE 0200843 A SE0200843 A SE 0200843A SE 0200843 A SE0200843 A SE 0200843A SE 0200843 D0 SE0200843 D0 SE 0200843D0
Authority
SE
Sweden
Prior art keywords
chemical compounds
compound
ccr3
chemokine
variables
Prior art date
Application number
SE0200843A
Other languages
English (en)
Swedish (sv)
Inventor
Hitesh Sanganee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200843A priority Critical patent/SE0200843D0/xx
Publication of SE0200843D0 publication Critical patent/SE0200843D0/xx
Priority to JP2003576426A priority patent/JP2005526089A/ja
Priority to AU2003212769A priority patent/AU2003212769A1/en
Priority to DE60321452T priority patent/DE60321452D1/de
Priority to AT03708798T priority patent/ATE397599T1/de
Priority to US10/508,332 priority patent/US7482363B2/en
Priority to ES03708798T priority patent/ES2305447T3/es
Priority to PCT/SE2003/000442 priority patent/WO2003078421A1/en
Priority to EP03708798A priority patent/EP1487817B1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0200843A 2002-03-19 2002-03-19 Chemical compounds SE0200843D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds
JP2003576426A JP2005526089A (ja) 2002-03-19 2003-03-17 ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体
AU2003212769A AU2003212769A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
DE60321452T DE60321452D1 (de) 2002-03-19 2003-03-17 Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
AT03708798T ATE397599T1 (de) 2002-03-19 2003-03-17 Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
US10/508,332 US7482363B2 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
ES03708798T ES2305447T3 (es) 2002-03-19 2003-03-17 Derivados de piperidina utiles como moduladores de la actividad del receptor de quimoquina.
PCT/SE2003/000442 WO2003078421A1 (en) 2002-03-19 2003-03-17 Piperidine derivatives useful as modulators of chemokine receptor activity
EP03708798A EP1487817B1 (de) 2002-03-19 2003-03-17 Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0200843D0 true SE0200843D0 (sv) 2002-03-19

Family

ID=20287325

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200843A SE0200843D0 (sv) 2002-03-19 2002-03-19 Chemical compounds

Country Status (9)

Country Link
US (1) US7482363B2 (de)
EP (1) EP1487817B1 (de)
JP (1) JP2005526089A (de)
AT (1) ATE397599T1 (de)
AU (1) AU2003212769A1 (de)
DE (1) DE60321452D1 (de)
ES (1) ES2305447T3 (de)
SE (1) SE0200843D0 (de)
WO (1) WO2003078421A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
EP1604982A1 (de) 2001-07-02 2005-12-14 AstraZeneca AB Zwischenverbindungen für die herstellung von piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6949590B2 (en) * 2002-01-10 2005-09-27 University Of Washington Hydrogels formed by non-covalent linkages
SE0200844D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
WO2006126948A1 (en) * 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
BRPI0613563A2 (pt) * 2005-07-21 2012-01-17 Astrazeneca Ab novos derivados de piperidina
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (de) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
AU2915892A (en) * 1991-11-14 1993-06-15 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en) 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
NZ333513A (en) 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0821954A1 (de) 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CZ43399A3 (cs) 1996-08-15 1999-07-14 Schering Corporation Etheroví muskarinní antagonisté
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
EP1052992A1 (de) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclische amine modulatoren der chemokinrezeptoren
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
CA2329777A1 (en) 1998-04-27 1999-11-04 Dashyant Dhanak Ccr-3 receptor antagonists
US6294555B1 (en) 1998-04-28 2001-09-25 Dainippon Pharmaceutical Co., Ltd. 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
CN1146559C (zh) 1998-06-30 2004-04-21 先灵公司 毒蕈碱性拮抗剂
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003529531A (ja) 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルXa因子阻害剤
CA2347912A1 (en) 1998-12-18 2000-06-22 Soo S. Ko Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CZ301161B6 (cs) 1999-05-04 2009-11-18 Schering Corporation Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
CA2382755A1 (en) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
US6294554B1 (en) * 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
IT1307809B1 (it) * 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB2373186A (en) 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
MXPA03008356A (es) 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
CZ20032636A3 (cs) 2001-03-29 2003-12-17 Schering Corporation Látky antagonizující CCR5
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
US7115635B2 (en) 2001-04-27 2006-10-03 Mitsubishi Pharma Corporation Benzylpiperidine compound
EP1604982A1 (de) * 2001-07-02 2005-12-14 AstraZeneca AB Zwischenverbindungen für die herstellung von piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0117899D0 (en) * 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
GB0122503D0 (en) * 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) * 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
RU2006100190A (ru) 2003-06-13 2006-08-10 Шеринг Акциенгезельшафт (De) Производные хинолиламида в качестве антагонистов ccr-5
SE0400925D0 (sv) 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
WO2006126948A1 (en) 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
TW200722419A (en) 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
BRPI0613563A2 (pt) 2005-07-21 2012-01-17 Astrazeneca Ab novos derivados de piperidina

Also Published As

Publication number Publication date
DE60321452D1 (de) 2008-07-17
AU2003212769A1 (en) 2003-09-29
EP1487817A1 (de) 2004-12-22
ATE397599T1 (de) 2008-06-15
EP1487817B1 (de) 2008-06-04
ES2305447T3 (es) 2008-11-01
JP2005526089A (ja) 2005-09-02
WO2003078421A1 (en) 2003-09-25
US7482363B2 (en) 2009-01-27
US20050182094A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
SE0301368D0 (sv) Chemical compounds
SE0202838D0 (sv) Chemical compounds
SE0300850D0 (sv) Chemical compounds
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
NL300933I2 (nl) Letermovir
MY128441A (en) Bipiperidine derivatives as modulators of ccr3 activity and as h1 antogonists
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
ATE433447T1 (de) Pyrimiidinverbindungen
SE0200844D0 (sv) Chemical compounds
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
TW200510317A (en) Caspase inhibitors and uses thereof
SE0300957D0 (sv) Chemical compounds
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
EA200600223A1 (ru) Замещённый 2-аминотетралины для лечения депрессии
DE60321452D1 (de) Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
PL1758852T3 (pl) Podstawione związki cyklopentenu
EP1794120A4 (de) Peptidaseinhibitoren
SE0400208D0 (sv) Chemical compounds
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE457982T1 (de) Thiazol-(bi)cycloalkyl-carboxanilide
SE0400925D0 (sv) Chemical compounds
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
TW200800942A (en) Chemical compounds
WO2005040129A3 (en) Ccr3 receptor antagonists
TW200722419A (en) Chemical compounds